Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies Inc. (NYSE: A) has launched a new eMethod for PFAS Analysis in Water using liquid chromatography and mass spectrometry. This solution enables rapid testing for over 100 PFAS compounds in drinking and surface water, significantly reducing analysis time from weeks to hours. The method aligns with evolving global regulations, helping environmental customers update their testing protocols. The comprehensive analytical workflow includes sample preparation, acquisition, and quantitation methods, ensuring compliance with current and future regulations.

MOBILion Systems Inc. has successfully completed a $60 million Series C financing round, led by D1 Capital Partners. This funding will support the commercialization of its first product, MOBIE®, a High-Resolution Ion Mobility tool designed for biopharmaceutical drug development. The technology aims to enhance the speed and accuracy of protein characterization, vital for quality monitoring in drug development. The company plans to expand its market presence, particularly in emerging fields like cell and gene therapy.

Agilent Technologies Inc. (NYSE: A) announced a significant study in partnership with Resolution Bioscience and Dana-Farber Cancer Institute, published in the New England Journal of Medicine. The study explores the clinical utility of liquid biopsy techniques for detecting resistance to KRAS G12C inhibitors like adagrasib in cancer treatment. It reveals diverse mutations leading to resistance, emphasizing the need for new therapeutic strategies. Notably, cfDNA analysis enabled more effective genotyping, improving patient outcomes in targeted therapies.

Agilent Technologies Inc. (NYSE: A) has launched three new InfinityLab Bio LC systems tailored for the biopharma industry. This portfolio includes the 1290 Infinity II Bio LC System with High-Speed Pump, 1290 Infinity II Bio LC System with Flexible Pump, and 1260 Infinity II Prime Bio LC System. These systems integrate with Agilent OpenLab and MassHunter software, enhancing efficiency in biopharma laboratories. The launch highlights Agilent's commitment to the growing biopharma LC market and introduces new workflow solutions to support bio-analytical requirements.

Agilent Technologies (NYSE: A) announced a presentation at the American Society of Clinical Oncology (ASCO) featuring the Resolution ctDx Lung test from Resolution Bioscience. The study, with over 1,000 patients, provides evidence for the clinical utility of this liquid biopsy in guiding targeted therapies for non-small cell lung cancer (NSCLC), showing a significant overall survival benefit. The findings highlight the advantages of liquid biopsies over traditional tissue tests, asserting Agilent's commitment to enhancing cancer diagnostics and precision oncology solutions.

Agilent Technologies (NYSE: A) has launched the SureSelect Human All Exon V8, enhancing exome sequencing capabilities for genomics research. This new design covers key protein coding regions along with hard-to-capture exons, offering options for routine, clinical, and translational research. The panel spans a 35.1 Mb target region, ensuring outstanding enrichment performance and cost-effective sequencing. Kevin Meldrum highlighted its significance in exome sequencing's growth, further supported by automation on the Bravo platform for efficient laboratory operations.

Agilent Technologies Inc. (NYSE: A) reported second-quarter revenue of $1.525 billion, marking a 23% increase year-over-year and 19% growth on a core basis. GAAP net income rose to $216 million or 70 cents per share from $101 million or 32 cents a year prior. Non-GAAP net income reached $299 million or 97 cents per share, compared to $223 million or 71 cents last year. The company raised its fiscal 2021 revenue outlook to between $6.15 billion and $6.21 billion, with non-GAAP earnings guidance adjusted to $4.09 to $4.14 per share.